JMP Securities Upgrades Insmed Incorporated to “Outperform” (INSM)
Insmed Incorporated (NASDAQ:INSM) was upgraded by JMP Securities from a “market perform” rating to an “outperform” rating in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm currently has a $25.00 price target on the stock. JMP Securities’ target price suggests a potential upside of 27.68% from the company’s current price.
A number of other analysts have also recently weighed in on INSM. Analysts at UBS AG reiterated a “buy” rating on shares of Insmed Incorporated in a research note to investors on Monday. They now have a $31.00 price target on the stock, up previously from $17.50. Separately, analysts at Piper Jaffray initiated coverage on shares of Insmed Incorporated in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $34.00 price target on the stock. Finally, analysts at HC Wainwright initiated coverage on shares of Insmed Incorporated in a research note to investors on Monday, November 11th. They set a “buy” rating and a $25.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, Insmed Incorporated presently has a consensus rating of “Buy” and a consensus target price of $27.80.
Insmed Incorporated (NASDAQ:INSM) traded up 6.01% during mid-day trading on Thursday, hitting $19.58. 704,093 shares of the company’s stock traded hands. Insmed Incorporated has a 1-year low of $5.56 and a 1-year high of $18.63. The stock’s 50-day moving average is $16.38 and its 200-day moving average is $14.0. The company’s market cap is $765.8 million.
Insmed Incorporated (NASDAQ:INSM) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.41) by $0.05. Analysts expect that Insmed Incorporated will post $-1.65 EPS for the current fiscal year.
Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company specializing in recombinant protein drug development.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.